{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T19:45:31Z","timestamp":1649187931439},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.2515\/therapie:2004011","type":"journal-article","created":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T15:42:11Z","timestamp":1173886931000},"page":"51-56","source":"Crossref","is-referenced-by-count":2,"title":["Importance de la pharmacologie in vivo dans la recherche fondamentale sur les m\u00e9dicaments psychotropes et leurs cibles biologiques"],"prefix":"10.1016","volume":"59","author":[{"given":"Jean","family":"Costentin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2004011_bb1185","series-title":"Animal models in psychiatry and neurology","first-page":"1","article-title":"Animal models: promises and problems","author":"Kornetsky","year":"1977"},{"key":"10.2515\/therapie:2004011_bb1190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1469-8986.1978.tb01390.x","article-title":"Prestimulus effects on human startle reflex in normals and schizophrenics","volume":"15","author":"Braff","year":"1978","journal-title":"Psychophysiology"},{"key":"10.2515\/therapie:2004011_bb1195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0091-3057(95)00160-X","article-title":"Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats","volume":"52","author":"Johansson","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.2515\/therapie:2004011_bb1200","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.2042-7158.1980.tb13018.x","article-title":"Evidence for thermoregulatory dopaminergic receptors located in the preopticus medialis nucleus of the rat hypothalamus","volume":"32","author":"Colboc","year":"1980","journal-title":"J Pharm Pharmacol"},{"key":"10.2515\/therapie:2004011_bb1205","article-title":"Rapid and dissociated changes in sensitivities of different dopamine receptors in mouse brain","volume":"407","author":"Costentin","year":"1975","journal-title":"Nature"},{"key":"10.2515\/therapie:2004011_bb1210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00506188","article-title":"Rat climbing behavior elicited by stimulation of cerebral dopamine receptors","volume":"325","author":"Protais","year":"1984","journal-title":"NaunynSchmiedebergs Arch Pharmacol"},{"key":"10.2515\/therapie:2004011_bb1215","first-page":"171","article-title":"Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y","volume":"110","author":"Inui","year":"1998","journal-title":"Proc Assoc Am Physicians"},{"key":"10.2515\/therapie:2004011_bb1220","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/41771","article-title":"Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor","volume":"388","author":"Ledent","year":"1997","journal-title":"Nature"},{"key":"10.2515\/therapie:2004011_bb1225","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0028-3908(00)00173-8","article-title":"Absence of the adenosine A2A receptor or its chronic blockade decreases ethanol withdrawal-induced seizures in mice","volume":"40","author":"El Yacoubi","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.2515\/therapie:2004011_bb1230","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0703170","article-title":"The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors","volume":"129","author":"El Yacoubi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie:2004011_bb1235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(00)00399-X","article-title":"SCH 58261 and ZM 241385 differentially prevent the motor effect of CGS 21680 in mice: evidence for a functional \u2018atypical\u2019 adenosine A2A receptor","volume":"401","author":"El Yacoubi","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.2515\/therapie:2004011_bb1240","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0028-3908(03)00254-5","article-title":"Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade","volume":"45","author":"El Yacoubi","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.2515\/therapie:2004011_bb1245","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00001756-200104170-00024","article-title":"Adenosine A2A receptor knockout mice are partially protected against drug induced catalepsy","volume":"12","author":"El Yacoubi","year":"2001","journal-title":"Neuroreport"},{"key":"10.2515\/therapie:2004011_bb1250","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1212\/01.WNL.0000095220.87550.F6","article-title":"Adenosine A2a receptors and depression","volume":"61","author":"El Yacoubi","year":"2003","journal-title":"Neurology"},{"key":"10.2515\/therapie:2004011_bb1255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjp.0704240","article-title":"Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A knockout mice","volume":"134","author":"El Yacoubi","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie:2004011_bb1260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s002130050037","article-title":"The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A2A adenosine receptor antagonists","volume":"148","author":"El Yacoubi","year":"2000","journal-title":"Psychopharmacology"},{"issue":"6879","key":"10.2515\/therapie:2004011_bb1265","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/416396a","article-title":"Serotonin 1A receptor acts during development to establish normal anxiety-like behaviour in the adult","volume":"416","author":"Gross","year":"2002","journal-title":"Nature"},{"key":"10.2515\/therapie:2004011_bb1270","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/0014-5793(94)80235-1","article-title":"ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization","volume":"341","author":"Mollereau","year":"1994","journal-title":"FEBS Lett"},{"key":"10.2515\/therapie:2004011_bb1275","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/377532a0","article-title":"Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor","volume":"377","author":"Meunier","year":"1995","journal-title":"Nature"},{"key":"10.2515\/therapie:2004011_bb1280","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.270.5237.792","article-title":"Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor","volume":"270","author":"Reinscheid","year":"1995","journal-title":"Science"},{"key":"10.2515\/therapie:2004011_bb1285","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1476-5381.1994.tb13077.x","article-title":"The non peptide neurotensin antagonist SR 48692 used as a tool to reveal putative neurotensin receptor subtypes","volume":"112","author":"Dubuc","year":"1994","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.2515\/therapie:2004011_bb1290","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1523\/JNEUROSCI.19-01-00503.1999","article-title":"Identification of the receptor subtype involved in the analgesic effect of neurotensin","volume":"19","author":"Dubuc","year":"1999","journal-title":"J Neurosci"},{"key":"10.2515\/therapie:2004011_bb1295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(99)00554-3","article-title":"The partial agonist properties of levocabastine in neurotensin-induced analgesia","volume":"381","author":"Dubuc","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2004011_bb1300","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(96)00800-X","article-title":"A genetic mouse model of helplessness sensitive to imipramine","volume":"316","author":"Vaugeois","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2004011_bb1305","first-page":"1149","article-title":"Founding a line of \u2018depressed\u2019 mice from the selection of breeds exhibiting a behavioural helplessness","volume":"192","author":"Vaugeois","year":"1998","journal-title":"C R Biol"},{"issue":"10","key":"10.2515\/therapie:2004011_bb1310","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1073\/pnas.1034823100","article-title":"Behavioral, neurochemical, and electro-physiological characterization of a genetic mouse model of depression","volume":"100","author":"El Yacoubi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1-2","key":"10.2515\/therapie:2004011_bb1315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0006-8993(02)02548-9","article-title":"A chronic treatment with fluoxetine decreases 5-HT (1A) receptors labeling in mice selected as a genetic model of helplessness","volume":"936","author":"Naudon","year":"2002","journal-title":"Brain Res"},{"key":"10.2515\/therapie:2004011_bb1320","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s002130050475","article-title":"Individual differences in response to imipramine in the mouse tail suspension test","volume":"134","author":"Vaugeois","year":"1997","journal-title":"Psychopharmacology"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T06:42:13Z","timestamp":1554273733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716301561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0040595716301561"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2004011","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}